Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial

Matteo Donadon¹, Marcello Di Martino², Cristina Rigamonti³

Affiliations

¹ Department of Health Sciences, University of Piemonte Orientale, Novara 28100, Italy; Department of Surgery, University Maggiore Hospital della Carità, Novara, Italy. Electronic address: matteo.donadon@uniupo.it.
² Department of Health Sciences, University of Piemonte Orientale, Novara 28100, Italy; Department of Surgery, University Maggiore Hospital della Carità, Novara, Italy.
³ Division of Internal Medicine, University Maggiore Hospital della Carità, Novara, Italy; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

PMID: 39153812
DOI: 10.1016/S0140-6736(24)00798-0

Comment

Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial

Matteo Donadon et al. Lancet. 2024.

. 2024 Aug 17;404(10453):655-656.

doi: 10.1016/S0140-6736(24)00798-0.

Authors

Matteo Donadon¹, Marcello Di Martino², Cristina Rigamonti³

Affiliations

¹ Department of Health Sciences, University of Piemonte Orientale, Novara 28100, Italy; Department of Surgery, University Maggiore Hospital della Carità, Novara, Italy. Electronic address: matteo.donadon@uniupo.it.
² Department of Health Sciences, University of Piemonte Orientale, Novara 28100, Italy; Department of Surgery, University Maggiore Hospital della Carità, Novara, Italy.
³ Division of Internal Medicine, University Maggiore Hospital della Carità, Novara, Italy; Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.

PMID: 39153812
DOI: 10.1016/S0140-6736(24)00798-0

No abstract available

PubMed Disclaimer

Comment in

Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
Chow PKH, Hack SP, Spahn JH, Yopp AC. Chow PKH, et al. Lancet. 2024 Aug 17;404(10453):657-658. doi: 10.1016/S0140-6736(24)00801-8. Lancet. 2024. PMID: 39153815 No abstract available.

Comment on

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial

Affiliations

Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial

Authors

Affiliations

Comment in

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical